Share Price and Basic Stock Data
Last Updated: December 10, 2025, 10:06 pm
| PEG Ratio | 1.19 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
RPG Life Sciences Ltd operates within the pharmaceuticals sector, a space often characterized by its resilience and growth potential. As of March 2025, the company reported sales of ₹653 Cr, a commendable increase from ₹513 Cr in the previous year. This upward trajectory reflects RPG’s ability to navigate market challenges effectively, particularly noteworthy given the industry’s competitive landscape. The latest quarterly sales figures also indicate a positive trend, with ₹172 Cr recorded in September 2024, showcasing a consistent growth pattern. The company’s ability to maintain sales momentum in a fluctuating market demonstrates a robust operational strategy and a solid product portfolio. However, it’s crucial to consider that while revenue growth appears strong, fluctuations in quarterly figures—such as a dip to ₹127 Cr in March 2024—might raise concerns about seasonality or market dependencies.
Profitability and Efficiency Metrics
RPG Life Sciences has showcased impressive profitability metrics, with a net profit of ₹183 Cr for FY 2025, significantly up from ₹68 Cr the previous year. This translates to a net profit margin of 28.04%, which is notably higher than the industry average, indicating effective cost management and pricing strategies. The operating profit margin (OPM) also rose to 25%, reflecting operational efficiency. Additionally, the company’s return on equity (ROE) stood at a robust 34.53%, suggesting that shareholder equity is being effectively utilized to generate profits. However, it’s worth mentioning that the company’s cash conversion cycle (CCC) of 72 days could be seen as a risk, as it indicates the time taken to convert investments into cash. Investors should monitor whether this metric stabilizes or improves, as prolonged cash cycles can signal potential liquidity issues.
Balance Sheet Strength and Financial Ratios
The balance sheet of RPG Life Sciences presents a picture of solid financial health. The company reported zero borrowings, a significant strength that positions it favorably against competitors laden with debt. With reserves amounting to ₹541 Cr, the company has a strong cushion to support future growth initiatives. The current ratio of 3.88 indicates a comfortable liquidity position, suggesting that RPG can easily meet its short-term obligations. Furthermore, the interest coverage ratio (ICR) of 277.95x underscores the company’s ability to cover interest expenses multiple times over, reinforcing its financial stability. However, the price-to-book value ratio at 7.10x may raise eyebrows among value investors, as it suggests that the stock could be overvalued relative to its book value. Thus, while the balance sheet appears robust, the valuation metrics warrant cautious scrutiny.
Shareholding Pattern and Investor Confidence
The shareholding structure of RPG Life Sciences reveals a strong promoter backing, with promoters holding 72.95% of the shares as of March 2025. This high level of insider ownership is generally seen as a positive signal, indicating confidence in the company’s future. Institutional investors, including domestic and foreign institutions, hold a modest share of 7.81%, which reflects a growing interest in the company from the institutional side. However, the relatively low foreign institutional investment (FIIs) of 1.11% may indicate some hesitancy in the international investment community. The public shareholding at 19.23% reveals a solid retail investor base, which is crucial for liquidity. The increasing number of shareholders—26,657 as of March 2025—suggests a growing interest and confidence among the retail segment, which could be a positive indicator for future stock performance.
Outlook, Risks, and Final Insight
As RPG Life Sciences navigates the competitive pharmaceutical landscape, several factors could influence its trajectory. On the positive side, the strong profitability metrics and robust balance sheet provide a solid foundation for growth, while the increasing sales figures suggest effective market strategies. However, potential risks include the company’s cash conversion cycle, which, if not managed, could create liquidity challenges. Additionally, the high price-to-book ratio may deter value-focused investors. Looking ahead, while the company seems well-positioned to capitalize on growth opportunities, investors should remain vigilant about market dynamics and internal operational challenges. Overall, RPG Life Sciences presents an intriguing case—one that blends potential with caution, urging investors to weigh the strengths and risks carefully before making decisions.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of RPG Life Sciences Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 142 Cr. | 113 | 244/84.3 | 31.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,169 Cr. | 383 | 479/192 | 86.3 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.4 Cr. | 43.6 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 45.3 Cr. | 30.9 | 31.0/17.0 | 108 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,300.20 Cr | 1,152.20 | 52.34 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 129 | 135 | 131 | 118 | 148 | 154 | 154 | 127 | 165 | 172 | 173 | 143 | 169 |
| Expenses | 101 | 105 | 101 | 103 | 116 | 116 | 116 | 106 | 126 | 126 | 124 | 118 | 133 |
| Operating Profit | 28 | 30 | 29 | 16 | 32 | 37 | 38 | 21 | 39 | 46 | 49 | 25 | 35 |
| OPM % | 22% | 22% | 22% | 13% | 22% | 24% | 25% | 16% | 24% | 27% | 28% | 18% | 21% |
| Other Income | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | -25 | 3 | 115 | 5 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 |
| Profit before tax | 25 | 27 | 26 | 14 | 30 | 35 | 36 | 18 | 36 | 15 | 47 | 135 | 35 |
| Tax % | 28% | 26% | 26% | 25% | 26% | 26% | 26% | 25% | 26% | 72% | 26% | 13% | 26% |
| Net Profit | 18 | 20 | 19 | 10 | 22 | 26 | 26 | 13 | 27 | 4 | 35 | 117 | 26 |
| EPS in Rs | 11.01 | 12.07 | 11.55 | 6.26 | 13.36 | 15.64 | 16.00 | 8.01 | 16.18 | 2.54 | 21.12 | 70.95 | 15.90 |
Last Updated: August 1, 2025, 1:05 pm
Below is a detailed analysis of the quarterly data for RPG Life Sciences Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 169.00 Cr.. The value appears strong and on an upward trend. It has increased from 143.00 Cr. (Mar 2025) to 169.00 Cr., marking an increase of 26.00 Cr..
- For Expenses, as of Jun 2025, the value is 133.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 118.00 Cr. (Mar 2025) to 133.00 Cr., marking an increase of 15.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 35.00 Cr.. The value appears strong and on an upward trend. It has increased from 25.00 Cr. (Mar 2025) to 35.00 Cr., marking an increase of 10.00 Cr..
- For OPM %, as of Jun 2025, the value is 21.00%. The value appears strong and on an upward trend. It has increased from 18.00% (Mar 2025) to 21.00%, marking an increase of 3.00%.
- For Other Income, as of Jun 2025, the value is 5.00 Cr.. The value appears to be declining and may need further review. It has decreased from 115.00 Cr. (Mar 2025) to 5.00 Cr., marking a decrease of 110.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 5.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 35.00 Cr.. The value appears to be declining and may need further review. It has decreased from 135.00 Cr. (Mar 2025) to 35.00 Cr., marking a decrease of 100.00 Cr..
- For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 13.00% (Mar 2025) to 26.00%, marking an increase of 13.00%.
- For Net Profit, as of Jun 2025, the value is 26.00 Cr.. The value appears to be declining and may need further review. It has decreased from 117.00 Cr. (Mar 2025) to 26.00 Cr., marking a decrease of 91.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 15.90. The value appears to be declining and may need further review. It has decreased from 70.95 (Mar 2025) to 15.90, marking a decrease of 55.05.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 23, 2025, 2:10 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 236 | 242 | 279 | 294 | 344 | 330 | 376 | 389 | 440 | 513 | 582 | 653 | 657 |
| Expenses | 224 | 228 | 256 | 274 | 306 | 296 | 315 | 318 | 353 | 408 | 453 | 493 | 501 |
| Operating Profit | 12 | 14 | 23 | 20 | 38 | 34 | 60 | 71 | 87 | 104 | 129 | 161 | 156 |
| OPM % | 5% | 6% | 8% | 7% | 11% | 10% | 16% | 18% | 20% | 20% | 22% | 25% | 24% |
| Other Income | 66 | 1 | 1 | 18 | 1 | 1 | -5 | 1 | 3 | 4 | 7 | 95 | 98 |
| Interest | 3 | 3 | 2 | 4 | 5 | 5 | 3 | 2 | 1 | 1 | 1 | 2 | 1 |
| Depreciation | 11 | 11 | 10 | 11 | 14 | 15 | 16 | 16 | 16 | 16 | 17 | 21 | 21 |
| Profit before tax | 65 | 1 | 12 | 23 | 20 | 15 | 36 | 54 | 73 | 92 | 118 | 233 | 232 |
| Tax % | 18% | 0% | 0% | 10% | 34% | 28% | 20% | 25% | 30% | 26% | 26% | 21% | |
| Net Profit | 53 | 1 | 12 | 21 | 13 | 11 | 29 | 40 | 51 | 68 | 88 | 183 | 183 |
| EPS in Rs | 32.29 | 0.60 | 7.03 | 12.70 | 8.13 | 6.54 | 17.54 | 24.19 | 31.13 | 40.90 | 53.00 | 110.79 | 110.51 |
| Dividend Payout % | 6% | 132% | 23% | 22% | 30% | 37% | 23% | 30% | 31% | 29% | 30% | 22% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -98.11% | 1100.00% | 75.00% | -38.10% | -15.38% | 163.64% | 37.93% | 27.50% | 33.33% | 29.41% | 107.95% |
| Change in YoY Net Profit Growth (%) | 0.00% | 1198.11% | -1025.00% | -113.10% | 22.71% | 179.02% | -125.71% | -10.43% | 5.83% | -3.92% | 78.54% |
RPG Life Sciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 12% |
| 3 Years: | 14% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 63% |
| 5 Years: | 29% |
| 3 Years: | 31% |
| TTM: | 12% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 32% |
| 5 Years: | 46% |
| 3 Years: | 46% |
| 1 Year: | 6% |
| Return on Equity | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 24% |
| 3 Years: | 25% |
| Last Year: | 26% |
Last Updated: September 5, 2025, 1:10 pm
Balance Sheet
Last Updated: December 4, 2025, 1:54 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 113 | 112 | 120 | 134 | 142 | 147 | 163 | 203 | 243 | 294 | 362 | 517 | 541 |
| Borrowings | 15 | 33 | 23 | 45 | 54 | 36 | 12 | 2 | 1 | 0 | 0 | 0 | 0 |
| Other Liabilities | 56 | 39 | 49 | 55 | 82 | 54 | 78 | 85 | 88 | 112 | 138 | 127 | 152 |
| Total Liabilities | 196 | 197 | 205 | 247 | 291 | 251 | 267 | 303 | 345 | 419 | 513 | 658 | 706 |
| Fixed Assets | 106 | 105 | 109 | 137 | 131 | 128 | 123 | 113 | 104 | 124 | 114 | 172 | 179 |
| CWIP | 1 | 1 | 2 | 2 | 9 | 17 | 10 | 12 | 31 | 25 | 96 | 16 | 27 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 58 | 91 | 127 | 93 |
| Other Assets | 89 | 92 | 94 | 108 | 152 | 106 | 134 | 178 | 210 | 211 | 212 | 343 | 407 |
| Total Assets | 196 | 197 | 205 | 247 | 291 | 251 | 267 | 303 | 345 | 419 | 513 | 658 | 706 |
Below is a detailed analysis of the balance sheet data for RPG Life Sciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 13.00 Cr..
- For Reserves, as of Sep 2025, the value is 541.00 Cr.. The value appears strong and on an upward trend. It has increased from 517.00 Cr. (Mar 2025) to 541.00 Cr., marking an increase of 24.00 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 152.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 127.00 Cr. (Mar 2025) to 152.00 Cr., marking an increase of 25.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 706.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 658.00 Cr. (Mar 2025) to 706.00 Cr., marking an increase of 48.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 179.00 Cr.. The value appears strong and on an upward trend. It has increased from 172.00 Cr. (Mar 2025) to 179.00 Cr., marking an increase of 7.00 Cr..
- For CWIP, as of Sep 2025, the value is 27.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Mar 2025) to 27.00 Cr., marking an increase of 11.00 Cr..
- For Investments, as of Sep 2025, the value is 93.00 Cr.. The value appears to be declining and may need further review. It has decreased from 127.00 Cr. (Mar 2025) to 93.00 Cr., marking a decrease of 34.00 Cr..
- For Other Assets, as of Sep 2025, the value is 407.00 Cr.. The value appears strong and on an upward trend. It has increased from 343.00 Cr. (Mar 2025) to 407.00 Cr., marking an increase of 64.00 Cr..
- For Total Assets, as of Sep 2025, the value is 706.00 Cr.. The value appears strong and on an upward trend. It has increased from 658.00 Cr. (Mar 2025) to 706.00 Cr., marking an increase of 48.00 Cr..
Notably, the Reserves (541.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -3.00 | -19.00 | 0.00 | -25.00 | -16.00 | -2.00 | 48.00 | 69.00 | 86.00 | 104.00 | 129.00 | 161.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 56 | 61 | 48 | 49 | 72 | 43 | 62 | 54 | 27 | 27 | 31 | 48 |
| Inventory Days | 180 | 149 | 156 | 163 | 171 | 136 | 133 | 162 | 214 | 203 | 200 | 159 |
| Days Payable | 176 | 109 | 135 | 102 | 165 | 83 | 127 | 132 | 117 | 138 | 140 | 135 |
| Cash Conversion Cycle | 60 | 101 | 70 | 110 | 78 | 96 | 68 | 84 | 124 | 91 | 90 | 72 |
| Working Capital Days | 30 | 27 | 26 | 20 | 22 | 20 | 41 | 52 | 47 | 33 | 25 | 45 |
| ROCE % | 2% | 2% | 9% | 10% | 13% | 10% | 23% | 27% | 31% | 33% | 35% | 33% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Multi Cap Fund | 176,287 | 0.43 | 39.39 | N/A | N/A | N/A |
| Union Small Cap Fund | 55,596 | 0.73 | 12.42 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 |
| Basic EPS (Rs.) | 110.80 | 53.01 | 40.90 | 31.13 | 24.19 |
| Diluted EPS (Rs.) | 110.80 | 53.01 | 40.90 | 31.13 | 24.19 |
| Cash EPS (Rs.) | 123.76 | 63.33 | 50.27 | 40.60 | 34.15 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 320.80 | 226.67 | 186.00 | 154.66 | 130.88 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 320.80 | 226.67 | 186.00 | 154.66 | 130.88 |
| Dividend / Share (Rs.) | 24.00 | 16.00 | 12.00 | 9.60 | 7.20 |
| Revenue From Operations / Share (Rs.) | 395.12 | 351.96 | 310.09 | 266.16 | 235.31 |
| PBDIT / Share (Rs.) | 104.20 | 81.85 | 65.00 | 54.03 | 42.84 |
| PBIT / Share (Rs.) | 91.25 | 71.53 | 55.62 | 44.56 | 32.88 |
| PBT / Share (Rs.) | 140.82 | 71.26 | 55.44 | 44.24 | 32.40 |
| Net Profit / Share (Rs.) | 110.80 | 53.01 | 40.90 | 31.13 | 24.19 |
| PBDIT Margin (%) | 26.37 | 23.25 | 20.96 | 20.29 | 18.20 |
| PBIT Margin (%) | 23.09 | 20.32 | 17.93 | 16.74 | 13.97 |
| PBT Margin (%) | 35.63 | 20.24 | 17.87 | 16.62 | 13.76 |
| Net Profit Margin (%) | 28.04 | 15.06 | 13.19 | 11.69 | 10.27 |
| Return on Networth / Equity (%) | 34.53 | 23.38 | 21.98 | 20.12 | 18.48 |
| Return on Capital Employeed (%) | 28.04 | 30.97 | 29.05 | 27.86 | 24.30 |
| Return On Assets (%) | 27.85 | 17.09 | 16.12 | 14.93 | 13.18 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Asset Turnover Ratio (%) | 1.12 | 1.25 | 1.34 | 1.36 | 1.37 |
| Current Ratio (X) | 3.88 | 2.28 | 2.57 | 2.58 | 2.21 |
| Quick Ratio (X) | 3.11 | 1.50 | 1.64 | 1.55 | 1.47 |
| Inventory Turnover Ratio (X) | 1.14 | 1.23 | 0.96 | 1.25 | 1.63 |
| Dividend Payout Ratio (NP) (%) | 14.44 | 22.64 | 23.47 | 23.13 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 12.92 | 18.95 | 19.10 | 17.73 | 0.00 |
| Earning Retention Ratio (%) | 85.56 | 77.36 | 76.53 | 76.87 | 0.00 |
| Cash Earning Retention Ratio (%) | 87.08 | 81.05 | 80.90 | 82.27 | 0.00 |
| Interest Coverage Ratio (X) | 277.95 | 300.80 | 346.74 | 171.83 | 89.67 |
| Interest Coverage Ratio (Post Tax) (X) | 163.32 | 195.80 | 219.19 | 100.00 | 51.63 |
| Enterprise Value (Cr.) | 3626.89 | 2494.10 | 1093.81 | 855.55 | 600.68 |
| EV / Net Operating Revenue (X) | 5.55 | 4.29 | 2.13 | 1.94 | 1.54 |
| EV / EBITDA (X) | 21.05 | 18.43 | 10.18 | 9.58 | 8.48 |
| MarketCap / Net Operating Revenue (X) | 5.76 | 4.35 | 2.24 | 2.10 | 1.65 |
| Retention Ratios (%) | 85.55 | 77.35 | 76.52 | 76.86 | 0.00 |
| Price / BV (X) | 7.10 | 6.75 | 3.74 | 3.62 | 2.96 |
| Price / Net Operating Revenue (X) | 5.76 | 4.35 | 2.24 | 2.10 | 1.65 |
| EarningsYield | 0.04 | 0.03 | 0.05 | 0.05 | 0.06 |
After reviewing the key financial ratios for RPG Life Sciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 8.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 8.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 110.80. This value is within the healthy range. It has increased from 53.01 (Mar 24) to 110.80, marking an increase of 57.79.
- For Diluted EPS (Rs.), as of Mar 25, the value is 110.80. This value is within the healthy range. It has increased from 53.01 (Mar 24) to 110.80, marking an increase of 57.79.
- For Cash EPS (Rs.), as of Mar 25, the value is 123.76. This value is within the healthy range. It has increased from 63.33 (Mar 24) to 123.76, marking an increase of 60.43.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 320.80. It has increased from 226.67 (Mar 24) to 320.80, marking an increase of 94.13.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 320.80. It has increased from 226.67 (Mar 24) to 320.80, marking an increase of 94.13.
- For Dividend / Share (Rs.), as of Mar 25, the value is 24.00. This value exceeds the healthy maximum of 3. It has increased from 16.00 (Mar 24) to 24.00, marking an increase of 8.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 395.12. It has increased from 351.96 (Mar 24) to 395.12, marking an increase of 43.16.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 104.20. This value is within the healthy range. It has increased from 81.85 (Mar 24) to 104.20, marking an increase of 22.35.
- For PBIT / Share (Rs.), as of Mar 25, the value is 91.25. This value is within the healthy range. It has increased from 71.53 (Mar 24) to 91.25, marking an increase of 19.72.
- For PBT / Share (Rs.), as of Mar 25, the value is 140.82. This value is within the healthy range. It has increased from 71.26 (Mar 24) to 140.82, marking an increase of 69.56.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 110.80. This value is within the healthy range. It has increased from 53.01 (Mar 24) to 110.80, marking an increase of 57.79.
- For PBDIT Margin (%), as of Mar 25, the value is 26.37. This value is within the healthy range. It has increased from 23.25 (Mar 24) to 26.37, marking an increase of 3.12.
- For PBIT Margin (%), as of Mar 25, the value is 23.09. This value exceeds the healthy maximum of 20. It has increased from 20.32 (Mar 24) to 23.09, marking an increase of 2.77.
- For PBT Margin (%), as of Mar 25, the value is 35.63. This value is within the healthy range. It has increased from 20.24 (Mar 24) to 35.63, marking an increase of 15.39.
- For Net Profit Margin (%), as of Mar 25, the value is 28.04. This value exceeds the healthy maximum of 10. It has increased from 15.06 (Mar 24) to 28.04, marking an increase of 12.98.
- For Return on Networth / Equity (%), as of Mar 25, the value is 34.53. This value is within the healthy range. It has increased from 23.38 (Mar 24) to 34.53, marking an increase of 11.15.
- For Return on Capital Employeed (%), as of Mar 25, the value is 28.04. This value is within the healthy range. It has decreased from 30.97 (Mar 24) to 28.04, marking a decrease of 2.93.
- For Return On Assets (%), as of Mar 25, the value is 27.85. This value is within the healthy range. It has increased from 17.09 (Mar 24) to 27.85, marking an increase of 10.76.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.12. It has decreased from 1.25 (Mar 24) to 1.12, marking a decrease of 0.13.
- For Current Ratio (X), as of Mar 25, the value is 3.88. This value exceeds the healthy maximum of 3. It has increased from 2.28 (Mar 24) to 3.88, marking an increase of 1.60.
- For Quick Ratio (X), as of Mar 25, the value is 3.11. This value exceeds the healthy maximum of 2. It has increased from 1.50 (Mar 24) to 3.11, marking an increase of 1.61.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 4. It has decreased from 1.23 (Mar 24) to 1.14, marking a decrease of 0.09.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 14.44. This value is below the healthy minimum of 20. It has decreased from 22.64 (Mar 24) to 14.44, marking a decrease of 8.20.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 12.92. This value is below the healthy minimum of 20. It has decreased from 18.95 (Mar 24) to 12.92, marking a decrease of 6.03.
- For Earning Retention Ratio (%), as of Mar 25, the value is 85.56. This value exceeds the healthy maximum of 70. It has increased from 77.36 (Mar 24) to 85.56, marking an increase of 8.20.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 87.08. This value exceeds the healthy maximum of 70. It has increased from 81.05 (Mar 24) to 87.08, marking an increase of 6.03.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 277.95. This value is within the healthy range. It has decreased from 300.80 (Mar 24) to 277.95, marking a decrease of 22.85.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 163.32. This value is within the healthy range. It has decreased from 195.80 (Mar 24) to 163.32, marking a decrease of 32.48.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,626.89. It has increased from 2,494.10 (Mar 24) to 3,626.89, marking an increase of 1,132.79.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 5.55. This value exceeds the healthy maximum of 3. It has increased from 4.29 (Mar 24) to 5.55, marking an increase of 1.26.
- For EV / EBITDA (X), as of Mar 25, the value is 21.05. This value exceeds the healthy maximum of 15. It has increased from 18.43 (Mar 24) to 21.05, marking an increase of 2.62.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.76. This value exceeds the healthy maximum of 3. It has increased from 4.35 (Mar 24) to 5.76, marking an increase of 1.41.
- For Retention Ratios (%), as of Mar 25, the value is 85.55. This value exceeds the healthy maximum of 70. It has increased from 77.35 (Mar 24) to 85.55, marking an increase of 8.20.
- For Price / BV (X), as of Mar 25, the value is 7.10. This value exceeds the healthy maximum of 3. It has increased from 6.75 (Mar 24) to 7.10, marking an increase of 0.35.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.76. This value exceeds the healthy maximum of 3. It has increased from 4.35 (Mar 24) to 5.76, marking an increase of 1.41.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in RPG Life Sciences Ltd:
- Net Profit Margin: 28.04%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 28.04% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 34.53% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 163.32
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.11
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 34.2 (Industry average Stock P/E: 52.34)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 28.04%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | RPG House, Mumbai Maharashtra 400030 | investorservices@rpgls.com http://www.rpglifesciences.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Harsh V Goenka | Chairman |
| Mr. Ashok Nair | Managing Director |
| Mr. Rajat Bhargava | Non Executive Director |
| Mr. Yugal Sikri | Non Executive Director |
| Ms. Vasundhara Patni | Non Executive Director |
| Mr. Manoj K Maheshwari | Independent Director |
| Ms. Zahabiya Khorakiwala | Independent Director |
| Mr. Bhaskar Iyer | Independent Director |
| Mr. Sachin Nandgaonkar | Independent Director |
| Ms. Radhika Gupta | Independent Director |
| Mr. Hiten Kotak | Independent Director |
| Mr. Anil Matai | Independent Director |
FAQ
What is the intrinsic value of RPG Life Sciences Ltd?
RPG Life Sciences Ltd's intrinsic value (as of 10 December 2025) is 2357.56 which is 2.59% higher the current market price of 2,298.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 3,814 Cr. market cap, FY2025-2026 high/low of 2,725/1,772, reserves of ₹541 Cr, and liabilities of 706 Cr.
What is the Market Cap of RPG Life Sciences Ltd?
The Market Cap of RPG Life Sciences Ltd is 3,814 Cr..
What is the current Stock Price of RPG Life Sciences Ltd as on 10 December 2025?
The current stock price of RPG Life Sciences Ltd as on 10 December 2025 is 2,298.
What is the High / Low of RPG Life Sciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of RPG Life Sciences Ltd stocks is 2,725/1,772.
What is the Stock P/E of RPG Life Sciences Ltd?
The Stock P/E of RPG Life Sciences Ltd is 34.2.
What is the Book Value of RPG Life Sciences Ltd?
The Book Value of RPG Life Sciences Ltd is 335.
What is the Dividend Yield of RPG Life Sciences Ltd?
The Dividend Yield of RPG Life Sciences Ltd is 0.87 %.
What is the ROCE of RPG Life Sciences Ltd?
The ROCE of RPG Life Sciences Ltd is 32.8 %.
What is the ROE of RPG Life Sciences Ltd?
The ROE of RPG Life Sciences Ltd is 25.5 %.
What is the Face Value of RPG Life Sciences Ltd?
The Face Value of RPG Life Sciences Ltd is 8.00.